Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07464210) titled 'Nemtabrutinib, Bortezomib, and Rituximab for WM' on March 2.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Seoul National University Hospital

Condition: Waldenstrom Macroglobulinemia

Intervention: Drug: NEBULA

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: June 1, 2026

Target Sample Size: 19

Countries of Recruitment: South Korea

To know more, visit https://clinicaltrials.gov/study/NCT07464210

Published by HT Digital Content Services with permi...